1. Generics Bulletin

Zydus’s ‘Transparency Failure’ Leads To Block On Indian Perjeta Biosimilar

Delhi Court’s Injunctive Relief Follows Recent Agreement With Dr Reddy’s

 
• By Dean Rudge

“The principles of fairness in procedural conduct, especially in commercial disputes, is crucial,” Delhi’s High Court told Zydus Lifesciences as it agreed to temporarily block the sale of the firm’s recently launched biosimilar to Roche’s Perjeta.

Indian flag
• Source: Shutterstock

India’s Delhi High Court has signed off an interim injunction blocking the sale of Zydus Lifesciences’ Sigrima biosimilar version of Roche’s Perjeta (pertuzumab), after the Indian firm failed to disclose to the court that it had earlier received a conditional approval for – and later launched – its biosimilar.

Such action “suggests a strategic move by the defendant to establish a market presence before any potential judicial restrictions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin